The company has received approvals for its three investigational new drugs (INDs). These INDs are used in the treatment of chronic obstructive pulmonary disease (COPD), dyslipidemia and artherosclerosis and associated cardiovascular diseases.
The pharma major has also announced that it will merge its Drug Discovery operations with its wholly owned subsidiary Aurigene, effective from July 1, 2009. Apart from this the company will set up a new unit to focus on Proprietary Products development, which will take care of building the proprietary, branded R&D portfolio in collaboration with various partners and service providers.
The new unit will own and manage the company’s all existing intellectual property, Dr. Reddy’s said.
The company will also close its research facility in Atlanta in the US as part of the reorganization.